CY1113190T1 - Μεθοδος αγωγης της αιμολυτικης νοσου - Google Patents

Μεθοδος αγωγης της αιμολυτικης νοσου

Info

Publication number
CY1113190T1
CY1113190T1 CY20121100783T CY121100783T CY1113190T1 CY 1113190 T1 CY1113190 T1 CY 1113190T1 CY 20121100783 T CY20121100783 T CY 20121100783T CY 121100783 T CY121100783 T CY 121100783T CY 1113190 T1 CY1113190 T1 CY 1113190T1
Authority
CY
Cyprus
Prior art keywords
treatment
hemolytic disease
hemolytic
complement
binds
Prior art date
Application number
CY20121100783T
Other languages
English (en)
Inventor
Leonard Bell
Russell P Rother
Original Assignee
Alexion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34808492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113190(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharmaceuticals, Inc. filed Critical Alexion Pharmaceuticals, Inc.
Publication of CY1113190T1 publication Critical patent/CY1113190T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Abstract

Η παροξυσμική νυκτερινή αιμοσφαιρινουρία ή άλλες αιμολυτικές νόσοι υποβάλλονται σε αγωγή δια της χρήσεως μίας ενώσεως που δεσμεύεται σε ή κατά τα άλλα καταστέλλει τη δημιουργία και/ή τη δράση ενός ή περισσότερων συνιστωσών του συμπληρώματος, όπως, για παράδειγμα, ενός αντισώματος ανασταλτικού του συμπληρώματος.
CY20121100783T 2004-02-03 2012-08-30 Μεθοδος αγωγης της αιμολυτικης νοσου CY1113190T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/771,552 US20050169921A1 (en) 2004-02-03 2004-02-03 Method of treating hemolytic disease
EP05712607A EP1720571B9 (en) 2004-02-03 2005-02-03 Method of treating hemolytic disease

Publications (1)

Publication Number Publication Date
CY1113190T1 true CY1113190T1 (el) 2016-04-13

Family

ID=34808492

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100783T CY1113190T1 (el) 2004-02-03 2012-08-30 Μεθοδος αγωγης της αιμολυτικης νοσου

Country Status (17)

Country Link
US (5) US20050169921A1 (el)
EP (7) EP2522363A1 (el)
JP (5) JP2007520494A (el)
KR (1) KR101197799B1 (el)
CN (4) CN1938047A (el)
AU (1) AU2005209854B2 (el)
CA (1) CA2554632A1 (el)
CY (1) CY1113190T1 (el)
DK (1) DK1720571T3 (el)
ES (1) ES2389093T3 (el)
HK (1) HK1094950A1 (el)
IL (2) IL177003A0 (el)
NZ (1) NZ549328A (el)
PL (1) PL1720571T3 (el)
PT (1) PT1720571E (el)
SI (1) SI1720571T1 (el)
WO (1) WO2005074607A2 (el)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
NZ538384A (en) * 2002-09-06 2009-04-30 Alexion Pharma Inc Treatment for asthma using a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components reptors, such as, C5a receptors
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) * 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) * 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
AU2005244012C1 (en) * 2004-05-14 2013-05-02 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006107708A1 (en) * 2005-04-04 2006-10-12 Alexion Pharmaceuticals, Inc. Treatment of disease caused by excess free hemoglobin
WO2007056227A2 (en) * 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
SI1988882T1 (sl) * 2006-03-02 2015-07-31 Alexion Pharmaceuticals, Inc. Podaljšanje preživetja alografta z inhibiranjem aktivnosti komplementa
CA3022097C (en) * 2006-03-15 2020-10-27 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
PL2698166T3 (pl) 2006-10-10 2016-03-31 Regenesance B V Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
PE20081259A1 (es) 2006-11-02 2008-10-31 Genentech Inc Anticuerpos anti-factor d humanizados
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
NZ602884A (en) 2008-04-11 2014-08-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
MY159396A (en) * 2008-08-05 2016-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
HRP20230167T1 (hr) * 2008-11-10 2023-03-31 Alexion Pharmaceuticals, Inc. Postupci i pripravci za liječenje poremećaja povezanih s komplementom
CA2971474C (en) * 2009-10-16 2022-11-22 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
US20110124019A1 (en) * 2009-11-25 2011-05-26 The Charlotte-Mecklenburg Hospital Authority Method of using carbonic anhydrase to detect hemolysis
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
JP5932670B2 (ja) * 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
KR102385507B1 (ko) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
AU2015230852B2 (en) * 2011-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. High concentration antibody formulations
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
ES2683307T3 (es) * 2011-04-08 2018-09-26 University Of Leicester Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2
EP2794656B1 (en) 2011-12-21 2019-02-27 Novartis AG Compositions comprising antibodies targeting factor p and c5
WO2013137912A2 (en) * 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
IN2014KN02324A (el) * 2012-04-06 2015-05-01 Omeros Corp
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
CA2897334A1 (en) * 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
EA201690213A1 (ru) 2013-08-12 2016-07-29 Дженентек, Инк. Композиции и способ лечения связанных с комплементом состояний
CN105683219B (zh) 2013-10-17 2020-07-14 奥默罗斯公司 用于治疗与masp-2依赖性补体活化有关的病况的方法
MA39934A (fr) 2014-05-01 2017-03-08 Hoffmann La Roche Variants d'anticorps anti-facteur d et leurs utilisations
AU2015365167B2 (en) 2014-12-19 2021-07-29 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies and methods of use
JP2018511557A (ja) 2015-01-22 2018-04-26 中外製薬株式会社 ２種以上の抗ｃ５抗体の組み合わせおよび使用方法
US20190135903A1 (en) * 2015-03-31 2019-05-09 Alexion Pharmaceuticals, Inc. Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
CA3027487A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
SG11201801024XA (en) 2016-08-05 2018-05-30 Chugai Pharmaceutical Co Ltd Therapeutic or preventive compositions for il-8-related diseases
IT201600121482A1 (it) * 2016-11-30 2018-05-30 Univ Degli Studi Di Verona Fattore H per l’uso nel trattamento e/o prevenzione della formazione di eterotrombi in pazienti affetti da anemia falciforme
SG10201908697XA (en) 2017-01-31 2019-10-30 Chugai Pharmaceutical Co Ltd A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
AU2018383751A1 (en) 2017-12-13 2020-06-25 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
CN112512656A (zh) 2018-05-30 2021-03-16 加利福尼亚大学董事会 用于组织和细胞聚集体解离及单细胞富集的微流体过滤装置及方法
CN112512563A (zh) 2018-08-01 2021-03-16 中外制药株式会社 用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法
MX2022001154A (es) 2019-07-31 2022-02-22 Hoffmann La Roche Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab.
TW202120124A (zh) 2019-07-31 2021-06-01 瑞士商赫孚孟拉羅股份公司 藉由使用抗c5抗體克羅伐單抗（crovalimab）之治療或預防c5相關疾病之劑量及投藥療程

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
DE3924924A1 (de) 1989-07-27 1991-02-07 Goetze Otto Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5650825A (en) * 1995-03-31 1997-07-22 Matsushita Electric Corporation Of America Method and apparatus for sending private data instead of stuffing bits in an MPEG bit stream
DE19826743A1 (de) * 1998-06-16 1999-12-23 Bayer Ag Verfahren zur Herstellung von geträgerten Polymerisationskatalysatorsystemen und Verwendung dieser zur Homo- und Copolymerisation ungesättigter Monomere
CA2436671C (en) * 2000-12-05 2015-02-03 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
AU2003223288A1 (en) * 2002-03-18 2003-10-08 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease

Also Published As

Publication number Publication date
JP2015083611A (ja) 2015-04-30
CN1938047A (zh) 2007-03-28
WO2005074607A3 (en) 2006-09-14
JP2011126917A (ja) 2011-06-30
US20050169921A1 (en) 2005-08-04
NZ549328A (en) 2010-12-24
EP2520311A2 (en) 2012-11-07
IL177003A0 (en) 2006-12-10
CA2554632A1 (en) 2005-08-18
KR101197799B1 (ko) 2012-11-05
CN103977402A (zh) 2014-08-13
KR101197799B9 (ko) 2024-02-08
EP1720571A4 (en) 2008-11-19
EP2910253A1 (en) 2015-08-26
JP2007520494A (ja) 2007-07-26
DK1720571T3 (da) 2012-09-03
US20110086040A1 (en) 2011-04-14
WO2005074607A2 (en) 2005-08-18
KR20070009996A (ko) 2007-01-19
PL1720571T3 (pl) 2012-11-30
JP2017057234A (ja) 2017-03-23
ES2389093T3 (es) 2012-10-23
EP2522363A1 (en) 2012-11-14
EP1720571B1 (en) 2012-06-13
US20100068202A1 (en) 2010-03-18
HK1094950A1 (en) 2007-04-20
JP5873047B2 (ja) 2016-03-01
US20120308559A1 (en) 2012-12-06
EP2520311A3 (en) 2012-11-14
EP2522361A1 (en) 2012-11-14
EP1720571B9 (en) 2012-10-24
EP2522364A1 (en) 2012-11-14
AU2005209854B2 (en) 2011-01-20
IL240410A0 (en) 2015-09-24
SI1720571T1 (sl) 2012-10-30
CN103446584A (zh) 2013-12-18
US20050191298A1 (en) 2005-09-01
CN103977403A (zh) 2014-08-13
PT1720571E (pt) 2012-08-29
AU2005209854A1 (en) 2005-08-18
EP1720571A2 (en) 2006-11-15
JP2013213044A (ja) 2013-10-17
EP2522362A1 (en) 2012-11-14

Similar Documents

Publication Publication Date Title
CY1113190T1 (el) Μεθοδος αγωγης της αιμολυτικης νοσου
CY1118978T1 (el) Μεθοδοι και συνθεσεις για την αυξηση της αποτελεσματικοτητας των θεραπευτικων αντισωματων με τη χρηση ενωσεων που διεγειρουν τα κυτταρα νκ
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1118349T1 (el) Παραγοντες συνδεσης me cd19 και χρησεις αυτων
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
CY1115730T1 (el) Θεραπευτικοι επιτοποι και χρησεις αυτων
CY1117617T1 (el) Αντισωματα ige εναντι ανθρωπου υψηλης συναφειας
EA200700225A1 (ru) Аналоги тетрапептида
CY1111995T1 (el) Χρηση ενος αναστολεα ibat για τη θεραπευτικη αντιμετωπιση ή προφυλαξη απο δυσκοιλιοτητα
CY1112798T1 (el) Ενωσεις διαρυλυδαντοϊνης
EA200802213A1 (ru) Способы лечения заболеваний крови
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
CY1114397T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν βακτηρια τα οποια μειωνουν οξαλικα
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
CY1107505T1 (el) Πουρινικες ενωσεις και χρησεις τους ως προσδεματα υποδοχεων κανναβιδοειδων
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
CY1105137T1 (el) Παραγωγα αμινοκυκλοεξυλ αιθερων και χρησεις τους
CY1115690T1 (el) Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων